专题：Advanced Breast Cancer Therapies

This cluster of papers focuses on the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as palbociclib, letrozole, ribociclib, and abemaciclib, in the treatment of hormone receptor-positive metastatic breast cancer. The papers cover various aspects including clinical trials, mechanisms of action, therapeutic resistance, combination strategies, and potential biomarkers.
最新文献
The kinase inhibitor palbociclib binds to HIV TAR RNA with very low nanomolar affinity and exquisite specificity

article Full Text OpenAlex

Three-dimensional structure of the palbociclib–HIV TAR complex

article Full Text OpenAlex

Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer

article Full Text OpenAlex

High PARP7 Expression is Associated with Higher Estrogen Response and Immune Suppression but Less Cell Proliferation and Better Survival in Breast Cancer

article Full Text OpenAlex

Abstract GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial

article Full Text OpenAlex

Abstract GS2-09: The single-arm confirmatory trial of tamoxifen alone without surgery for low-risk DCIS of the breast with ER-positive HER2-negative (LORETTA trial: JCOG1505)

article Full Text OpenAlex

Abstract PS4-07-27: Pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early-stage TNBC: a post hoc analysis of participants included and separately of those not included in the first interim analysis for pCR in the KEYNOTE-522 study

article Full Text OpenAlex

Abstract RF5-03: OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancer

article Full Text OpenAlex

Abstract GS1-08: Multimodal artificial intelligence (AI) models integrating image, clinical, and molecular data for predicting early and late breast cancer recurrence in TAILORx

article Full Text OpenAlex

Abstract RF2-04: Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high-risk early-stage triple-negative breast cancer (CITRINE): a phase 3 randomized trial

article Full Text OpenAlex

近5年高被引文献
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

article Full Text OpenAlex 2381 FWCI234.6018

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

review Full Text OpenAlex 1697 FWCI265.4519

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics

review Full Text OpenAlex 1509 FWCI146.0768

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

article Full Text OpenAlex 943 FWCI83.2642

Triple negative breast cancer: Pitfalls and progress

review Full Text OpenAlex 681 FWCI60.2805

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

article Full Text OpenAlex 656 FWCI94.0814

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

article Full Text OpenAlex 637 FWCI90.2816

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

article Full Text OpenAlex 615 FWCI161.8292

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

article Full Text OpenAlex 519 FWCI74.4747

Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)

review Full Text OpenAlex 502 FWCI70.5309